Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 11, Issue 1, Pages 124
Publisher
MDPI AG
Online
2021-12-28
DOI
10.3390/jcm11010124
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
- (2020) Valentine Suteau et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT‐20 and TtT/GF by affecting expression of MMP‐14 and ADAM12
- (2020) Zhuo Zhang et al. FEBS Open Bio
- Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
- (2020) Nazanin Majd et al. Journal for ImmunoTherapy of Cancer
- Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas
- (2019) Dongyun Zhang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review
- (2019) Yong Wang et al. World Neurosurgery
- Augmented Reality in Transsphenoidal Surgery
- (2019) Barbara Carl et al. World Neurosurgery
- 111In-pentetreotide scintigraphy vs. 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
- (2019) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA
- (2019) Chitra Choudhary et al. Endocrine Practice
- Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
- (2019) G Giuffrida et al. Endocrine Connections
- Immune checkpoint inhibitors: The linchpins of modern immunotherapy
- (2019) Breelyn A. Wilky IMMUNOLOGICAL REVIEWS
- Medical Management of Cushing Disease
- (2019) Nicholas A. Tritos et al. NEUROSURGERY CLINICS OF NORTH AMERICA
- Targeting PD-L1 initiates effective anti-tumor immunity in a murine model of Cushing's Disease
- (2019) Hanna R Kemeny et al. CLINICAL CANCER RESEARCH
- Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness
- (2019) Pedro Marques et al. ENDOCRINE-RELATED CANCER
- The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
- (2018) Matthew P. Salomon et al. CLINICAL CANCER RESEARCH
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Combined effects of resveratrol and radiation in GH3 and TtT/GF pituitary adenoma cells
- (2018) B. Voellger et al. JOURNAL OF NEURO-ONCOLOGY
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
- (2018) Shang-Gin Wu et al. Molecular Cancer
- EGFR-TKIs resistance via EGFR-independent signaling pathways
- (2018) Qian Liu et al. Molecular Cancer
- Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
- (2018) Hitisha K. Patel et al. PHARMACOLOGY & THERAPEUTICS
- Expression of Matrix Metalloproteinase-9, Pituitary Tumor Transforming Gene, High Mobility Group A 2, and Ki-67 in Adrenocorticotropic Hormone–Secreting Pituitary Tumors and Their Association with Tumor Recurrence
- (2018) Xiaohai Liu et al. World Neurosurgery
- Advances in the medical treatment of Cushing's syndrome
- (2018) Richard A Feelders et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
- (2018) André Lacroix et al. Lancet Diabetes & Endocrinology
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma
- (2018) Rafael L. Batista et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: A systematic study
- (2018) Ricarda Hannen et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endoscopic Versus Microscopic Transsphenoidal Surgery in the Treatment of Pituitary Adenoma: A Systematic Review and Meta-Analysis
- (2017) Aijun Li et al. World Neurosurgery
- Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists
- (2016) Y Greenman et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Cabergoline treatment for recurrent Cushing’s disease during pregnancy
- (2016) Afif Nakhleh et al. Hormones-International Journal of Endocrinology and Metabolism
- Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas
- (2016) Junwen Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro
- (2016) Shi-qi Cheng et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Microsatellite instability: an update
- (2015) Hiroyuki Yamamoto et al. ARCHIVES OF TOXICOLOGY
- Recurrent gain-of-function USP8 mutations in Cushing's disease
- (2015) Zeng-Yi Ma et al. CELL RESEARCH
- Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas andin vivoresponse to cabergoline therapy
- (2015) Leonardo Vieira Neto et al. CLINICAL ENDOCRINOLOGY
- ErbB Receptor-Driven Prolactinomas Respond to Targeted Lapatinib Treatment in Female Transgenic Mice
- (2015) Xiaohai Liu et al. ENDOCRINOLOGY
- Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients
- (2015) P. Burman et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas
- (2015) Güliz Demirelli Gültekin et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications
- (2015) Christian P. Miermeister et al. Acta Neuropathologica Communications
- The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
- (2014) Eric Monsalves et al. ENDOCRINE-RELATED CANCER
- Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease
- (2014) Susan M Webb et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Mutations in the deubiquitinase gene USP8 cause Cushing's disease
- (2014) Martin Reincke et al. NATURE GENETICS
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
- (2013) Jacqueline Trouillas et al. ACTA NEUROPATHOLOGICA
- mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features
- (2013) Emir Ahmed Sajjad et al. ENDOCRINE PATHOLOGY
- Bisphenol S Disrupts Estradiol-Induced Nongenomic Signaling in a Rat Pituitary Cell Line: Effects on Cell Functions
- (2013) René Viñas et al. ENVIRONMENTAL HEALTH PERSPECTIVES
- Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies
- (2013) Laura Chinezu et al. HUMAN PATHOLOGY
- High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)
- (2013) Brad E. Zacharia et al. NEUROSURGERY
- Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
- (2013) Jan Komor et al. Pituitary
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Resveratrol decreases B-cell lymphoma-2 expression and viability in GH3 pituitary adenoma cells of the rat
- (2013) Benjamin Voellger et al. OncoTargets and Therapy
- Carcinogenicity and hormone studies with the tissue-selective estrogen receptor modulator bazadoxifene
- (2012) David J. Wright et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
- (2012) Petra Hamerlik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- ADAM10 promotes pituitary adenoma cell migration by regulating cleavage of CD44 and L1
- (2012) Yuan Pan et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas
- (2012) Erica C. Garcia et al. Pituitary
- EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
- (2011) Hidenori Fukuoka et al. JOURNAL OF CLINICAL INVESTIGATION
- Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
- (2011) E. Vilar et al. MOLECULAR CANCER THERAPEUTICS
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report
- (2011) Marcos Paulo Manavela et al. Pituitary
- Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas
- (2011) Filip Gabalec et al. Pituitary
- Anti-VEGF therapy in pituitary carcinoma
- (2011) Leon D. Ortiz et al. Pituitary
- Estrogen- and xenoestrogen-induced ERK signaling in pituitary tumor cells involves estrogen receptor-α interactions with G protein-αi and caveolin I
- (2011) Cheryl S. Watson et al. STEROIDS
- Cabergoline monotherapy in the long-term treatment of Cushing's disease
- (2010) Ariane Godbout et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
- (2010) Chrisostomi Gialeli et al. FEBS Journal
- HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy
- (2010) Hidenori Fukuoka et al. MOLECULAR ENDOCRINOLOGY
- Membrane-impermeable estrogen is involved in regulation of calbindin-D9k expression via non-genomic pathways in a rat pituitary cell line, GH3 cells
- (2010) Vu Hoang Dang et al. TOXICOLOGY IN VITRO
- Epidermal growth factor receptor cross-talks with ligand-occupied estrogen receptor-α to modulate both lactotroph proliferation and prolactin gene expression
- (2009) Shenglin Chen et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Matrix metalloproteinases: Fold and function of their catalytic domains
- (2009) Cynthia Tallant et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro
- (2009) Alexander Gorshtein et al. ENDOCRINE-RELATED CANCER
- Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas
- (2009) Maria Chiara Zatelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Infiltrating Lymphocytes But Not Serum Pituitary Antibodies Are Associated with Poor Clinical Outcome after Surgery in Patients with Pituitary Adenoma
- (2009) Isabella Lupi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
- (2009) Roopali Roy et al. JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor
- (2009) Marie S. Thearle et al. Pituitary
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- Estrogen Receptor-α Mediates the Epidermal Growth Factor-Stimulated Prolactin Expression and Release in Lactotrophs
- (2008) Nira Ben-Jonathan et al. ENDOCRINOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started